Teva Pharma (TEVA) PT Lowered to $22 at Morgan Stanley
Tweet
Share
E-mail
Get Alerts TEVA Hot Sheet
Price: $37.47 +2.43%
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Join SI Premium – FREE
Morgan Stanley analyst David Risinger lowered the price target on Teva Pharma (NYSE: TEVA) to $22.00 (from $27.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Moderna (MRNA) PT Raised to $89 at Morgan Stanley
- CrowdStrike (CRWD) PT Adjusted $250 at Cantor Fitzgerald Post Stock Split
- BofA Securities Upgrades Moderna (MRNA) to Neutral
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
